Polymorphic forms of rifaximin
US9359374B2 · kind B2 · utility
2Cited by
7References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 13, 2013 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | Jun 13, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/22
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms APO-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.